Further analysis was performed, and it was revealed that the high SGOL1 expression level was associated with poor progression-free survival (PFS), disease-free survival (DFS), and disease-specific survival (DSS) in HCC patients (Figure 3A), thus, we selected HCC for the next step of our study. This evidence concerns the gene SGO1 and hepatocellular carcinoma.